Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/UACA_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/UACA_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/UACA_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/UACA_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/UACA_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0010952113 | Thyroid | PTC | positive regulation of peptidase activity | 94/5968 | 197/18723 | 2.34e-06 | 3.11e-05 | 94 |
GO:2000116113 | Thyroid | PTC | regulation of cysteine-type endopeptidase activity | 108/5968 | 235/18723 | 3.99e-06 | 4.99e-05 | 108 |
GO:0052547113 | Thyroid | PTC | regulation of peptidase activity | 191/5968 | 461/18723 | 7.82e-06 | 9.02e-05 | 191 |
GO:0052548113 | Thyroid | PTC | regulation of endopeptidase activity | 174/5968 | 432/18723 | 1.20e-04 | 9.55e-04 | 174 |
GO:0010950113 | Thyroid | PTC | positive regulation of endopeptidase activity | 80/5968 | 179/18723 | 2.09e-04 | 1.55e-03 | 80 |
GO:0043280112 | Thyroid | PTC | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 58/5968 | 129/18723 | 1.22e-03 | 6.97e-03 | 58 |
GO:003806113 | Thyroid | PTC | NIK/NF-kappaB signaling | 63/5968 | 143/18723 | 1.45e-03 | 8.12e-03 | 63 |
GO:2001056111 | Thyroid | PTC | positive regulation of cysteine-type endopeptidase activity | 64/5968 | 148/18723 | 2.33e-03 | 1.23e-02 | 64 |
GO:190122213 | Thyroid | PTC | regulation of NIK/NF-kappaB signaling | 49/5968 | 112/18723 | 5.42e-03 | 2.49e-02 | 49 |
GO:0043281210 | Thyroid | goiters | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 22/497 | 209/18723 | 4.23e-08 | 3.81e-06 | 22 |
GO:0052547210 | Thyroid | goiters | regulation of peptidase activity | 33/497 | 461/18723 | 2.68e-07 | 1.98e-05 | 33 |
GO:2000116210 | Thyroid | goiters | regulation of cysteine-type endopeptidase activity | 22/497 | 235/18723 | 3.36e-07 | 2.40e-05 | 22 |
GO:0052548210 | Thyroid | goiters | regulation of endopeptidase activity | 31/497 | 432/18723 | 5.88e-07 | 3.75e-05 | 31 |
GO:0045862210 | Thyroid | goiters | positive regulation of proteolysis | 28/497 | 372/18723 | 8.12e-07 | 4.73e-05 | 28 |
GO:001095229 | Thyroid | goiters | positive regulation of peptidase activity | 19/497 | 197/18723 | 1.36e-06 | 7.39e-05 | 19 |
GO:004328026 | Thyroid | goiters | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 15/497 | 129/18723 | 1.73e-06 | 9.18e-05 | 15 |
GO:001095027 | Thyroid | goiters | positive regulation of endopeptidase activity | 17/497 | 179/18723 | 5.98e-06 | 2.72e-04 | 17 |
GO:200105626 | Thyroid | goiters | positive regulation of cysteine-type endopeptidase activity | 15/497 | 148/18723 | 9.59e-06 | 3.93e-04 | 15 |
GO:190122222 | Thyroid | goiters | regulation of NIK/NF-kappaB signaling | 9/497 | 112/18723 | 2.99e-03 | 4.56e-02 | 9 |
GO:004586234 | Thyroid | ATC | positive regulation of proteolysis | 202/6293 | 372/18723 | 1.07e-16 | 9.42e-15 | 202 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
UACA | SNV | Missense_Mutation | | c.1948T>A | p.Leu650Ile | p.L650I | Q9BZF9 | protein_coding | tolerated(0.18) | benign(0.017) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UACA | SNV | Missense_Mutation | rs143107777 | c.2314N>G | p.Thr772Ala | p.T772A | Q9BZF9 | protein_coding | deleterious(0.03) | possibly_damaging(0.839) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
UACA | SNV | Missense_Mutation | rs753763851 | c.2704G>T | p.Asp902Tyr | p.D902Y | Q9BZF9 | protein_coding | deleterious(0) | benign(0.219) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UACA | SNV | Missense_Mutation | novel | c.2408T>G | p.Phe803Cys | p.F803C | Q9BZF9 | protein_coding | tolerated(0.08) | possibly_damaging(0.619) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UACA | SNV | Missense_Mutation | | c.2173G>A | p.Asp725Asn | p.D725N | Q9BZF9 | protein_coding | deleterious(0) | possibly_damaging(0.905) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UACA | SNV | Missense_Mutation | | c.3154N>C | p.Glu1052Gln | p.E1052Q | Q9BZF9 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
UACA | SNV | Missense_Mutation | | c.844N>T | p.Asp282Tyr | p.D282Y | Q9BZF9 | protein_coding | deleterious(0.02) | possibly_damaging(0.526) | TCGA-BH-A0B4-01 | Breast | breast invasive carcinoma | Male | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
UACA | SNV | Missense_Mutation | | c.4181N>T | p.Gly1394Val | p.G1394V | Q9BZF9 | protein_coding | deleterious(0) | possibly_damaging(0.875) | TCGA-BH-A0HX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adrimycin | SD |
UACA | SNV | Missense_Mutation | | c.3480G>C | p.Lys1160Asn | p.K1160N | Q9BZF9 | protein_coding | deleterious(0) | possibly_damaging(0.776) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UACA | SNV | Missense_Mutation | rs201992560 | c.3758A>C | p.Lys1253Thr | p.K1253T | Q9BZF9 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-E2-A14S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |